Repurposed transplant drug enters fight against deadly brain cancer
NCT ID NCT05236036
Summary
This early-stage trial is testing whether adding a drug called mycophenolate mofetil (MMF) to standard glioblastoma treatment is safe and might make the cancer more sensitive to chemotherapy. MMF is an immunosuppressant commonly used to prevent organ rejection after transplants. The study will enroll about 60 adults with newly diagnosed or recurrent glioblastoma to find the safest dose and see if the combination can help control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
-
Northwestern Medicine Warrenville
Warrenville, Illinois, 60555, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.